Journal: Cancers

Article Title: Dihydrotestosterone Enhances MICA-Mediated Immune Responses to Epstein-Barr Virus-Associated Gastric Carcinoma.

doi: 10.3390/cancers16183219

Figure Lengend Snippet: Figure 4. DHT increases the cytotoxicity of PBMCs. (A) Fresh PBMCs were treated (stimulated) with EBV EBNA1 full peptide (5 g/mL) and LMP2A full peptide (5 g/mL) for 14 days to establish EBNA1 PBMCs and LMP2A PBMCs, respectively. The proportion of CD8+ T cells in each of these two PBMCs was investigated by FACs analysis. The bright cyan letters and numbers in the dot plot represent the intensity and percentage of antibody binding to the antigen. Specifically, UL4 indicates the percentage of CD8-positive and CD3-negative cells, LL4 represents the percentage of CD8-negative and CD3-negative cells, UR4 corresponds to the percentage of CD8-positive and CD3-positive cells, and LR4 denotes the percentage of CD8-negative and CD3-positive cells. 1e1 means 1 × 101, which equals 10. 1e2 means 1 × 102, which equals 100. 1e3 means 1 × 103, which equals 1000. (B) The proportion of cells secreting INF-γ in each EBNA1 PBMCs and LMP2A PBMCs was examined by FACs analysis. (C) Investigation of cytotoxicity of EBNA1 PBMCs against SNU719 cells treated with 100 nM DHT for 24 h by LDH release-based cytotoxicity assay. Cytotoxicity of EBNA

Article Snippet: The EBV EBNA-1 peptide pool (#130-093- 613, Miltenyi Biotec, Bergisch Gladbach, Germany) was used to generate EBNA-1-specific PBMCs (named EBNA1 PBMCs), while the EBV LMP2A peptide pool (130-093-615, Miltenyi Biotec) was used to generate LMP2A-specific PBMCs (named LMP2A PBMCs).

Techniques: Binding Assay, Cytotoxicity Assay